5 CDMO attributes for successful late-phase tech transfers

Outsourcing projects to CDMOs is becoming increasingly prevalent as drug sponsors look to optimize their supply chain or conserve internal resources for other projects. In 2021 alone, 46% of newly developed drugs were outsourced. Drug sponsors can reap a variety of benefits by outsourcing late-phase projects, but it comes with risks. The technology transfer that must occur to transition a late-phase project to a CDMO is complex and costly. The average cost of a tech transfer is around $1M, so partnering with the wrong CDMO can be a costly mistake.